Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Autism: Can It Support Behavior, Communication, and Daily Function?
Transcript
- 0:00SPEAKER_00: Welcome to the Cirona Cell Podcast.
- 0:02SPEAKER_00: When we think about autism spectrum disorder, we uh we almost exclusively think about the brain.
- 0:08SPEAKER_01: Aaron Ross Powell Right, the neurology side of things.
- 0:10SPEAKER_00: Exactly.
- 0:11SPEAKER_00: Neurology, behavior, learning.
- 0:12SPEAKER_00: But what if the biggest roadblock to traditional therapy isn't actually starting in the brain at all?
- 0:17SPEAKER_01: Aaron Powell Yeah.
- 0:18SPEAKER_01: What if it's in the gut or the immune system?
- 0:20SPEAKER_00: Aaron Ross Powell Right, the whole biological environment.
- 0:22SPEAKER_01: Aaron Ross Powell It completely reframes how we look at it.
- 0:24SPEAKER_01: Because if we only look at the neurology, I mean, we are missing a massive piece of the physiological puzzle.
- 0:31SPEAKER_00: Aaron Powell You're just fighting a losing battle.
- 0:32SPEAKER_01: Aaron Ross Powell Absolutely.
- 0:33SPEAKER_01: When you ignore that underlying biology, you're just not getting the whole picture.
- 0:36SPEAKER_00: Aaron Powell Which brings us to today's deep dive.
- 0:39SPEAKER_00: We've got this fascinating stack of sources in front of us from Cerona Cell.
- 0:43SPEAKER_01: Trevor Burrus, yeah.
- 0:43SPEAKER_01: A doctor-led stem cell therapy and regenerative medicine center.
- 0:46SPEAKER_00: Aaron Powell Right, based in Kuala Lumpur, Malaysia, specifically in the cybergaya area.
- 0:51SPEAKER_00: And you know, this regenerative medicine space is moving so incredibly fast right now.
- 0:56SPEAKER_01: Aaron Ross Powell Oh, lightning fast.
- 0:57SPEAKER_01: Which brings a lot of hope, but also, well, a mountain of internet hype.
- 1:02SPEAKER_00: Exactly.
- 1:02SPEAKER_00: So today, our mission is to cut straight through that noise for you.
- 1:07SPEAKER_00: We're going to explore the actual science.
- 1:09SPEAKER_01: The rigorous safety protocols.
- 1:11SPEAKER_00: Yeah, and the realistic expectations around stem cell therapy.
- 1:15SPEAKER_00: Specifically looking at how it's being utilized as a supportive option for autism spectrum disorder.
- 1:21SPEAKER_01: Aaron Powell And I really want to emphasize that word supportive right out of the gate.
- 1:24SPEAKER_01: Today is about understanding the why and the how of cellular care.
- 1:29SPEAKER_00: Aaron Ross Powell Right.
- 1:30SPEAKER_00: The systemic mechanisms.
- 1:31SPEAKER_01: Aaron Powell Exactly.
- 1:32SPEAKER_01: So if you are listening to this hoping for a magic bullet or you know an overnight cure, we are going to disappoint you.
- 1:38SPEAKER_00: Aaron Powell Yeah, those don't exist.
- 1:40SPEAKER_01: Aaron Powell Right.
- 1:40SPEAKER_01: As the source material makes abundantly clear, those simply do not exist in ethical medicine.
- 1:46SPEAKER_00: Okay, let's unpack this.
- 1:47SPEAKER_01: Yeah.
- 1:47SPEAKER_00: Because to understand how cellular care even fits into this picture, we really have to look at how we traditionally view autism care.
- 1:54SPEAKER_00: Trevor Burrus, Jr.
- 1:54SPEAKER_01: Right.
- 1:54SPEAKER_01: The behavioral interventions.
- 1:55SPEAKER_00: Exactly.
- 1:56SPEAKER_00: Think of speech therapy, occupational therapy, structured learning support.
- 2:00SPEAKER_01: Which are incredibly important, obviously.
- 2:02SPEAKER_00: Oh, absolutely.
- 2:03SPEAKER_00: But the sources highlight this entirely different biological layer that, well, it often goes completely unaddressed in standard care.
- 2:11SPEAKER_00: Trevor Burrus, Jr.
- 2:11SPEAKER_01: Yeah, they point out that many individuals with autism also experience a severe cluster of physical symptoms.
- 2:18SPEAKER_01: Trevor Burrus, Jr.
- 2:18SPEAKER_00: Right.
- 2:18SPEAKER_00: Chronic gut concerns, severe allergies.
- 2:21SPEAKER_01: Frequent infections, and just this ongoing systemic inflammation.
- 2:25SPEAKER_00: Yes.
- 2:26SPEAKER_00: And that cluster of symptoms points to a core concept mentioned throughout the clinical texts.
- 2:32SPEAKER_01: Immune system imbalance.
- 2:33SPEAKER_00: Exactly.
- 2:34SPEAKER_01: Because if we connect this to the bigger picture, behavioral and neurodevelopmental challenges aren't just happening in a vacuum inside the skull.
- 2:41SPEAKER_00: The brain is intimately connected to the body's overall inflammatory state.
- 2:45SPEAKER_01: Right.
- 2:46SPEAKER_01: When a child or an adult on the spectrum is dealing with chronic gut issues or constant allergic responses, their immune system is essentially stuck in overdrive.
- 2:54SPEAKER_00: It's constantly sounding a biological alarm.
- 2:57SPEAKER_01: Exactly.
- 2:57SPEAKER_00: So let's put this into a framework that makes sense.
- 3:00SPEAKER_00: Think of behavioral therapy as like upgrading the software.
- 3:03SPEAKER_01: Oh, I like that.
- 3:04SPEAKER_00: Right.
- 3:04SPEAKER_00: You are teaching the brain new skills, new ways of processing information.
- 3:09SPEAKER_00: But if the body's immune system is chronically inflamed, the hardware is physically overheating.
- 3:16SPEAKER_01: That is a brilliant way to visualize it.
- 3:18SPEAKER_00: Because you can't successfully run complex new software on a hard drive that is constantly crashing.
- 3:24SPEAKER_01: You really can't.
- 3:25SPEAKER_01: You could have the best speech therapist in the world, the best software developer, right?
- 3:29SPEAKER_01: Yeah.
- 3:30SPEAKER_01: But if the biological hardware is highly inflamed and toxic, that individual is going to struggle to process and retain those new skills.
- 3:39SPEAKER_00: The therapies are just fighting an uphill battle against a hostile biological environment.
- 3:44SPEAKER_00: Exactly.
- 3:45SPEAKER_00: But I want to pause here and be absolutely clear for you listening, because this is where the internet hype usually gets things wrong.
- 3:51SPEAKER_00: The sources are very careful to say this biological intervention is not a replacement for those standard therapies, right?
- 3:56SPEAKER_01: Not at all.
- 3:57SPEAKER_00: If you cool down the hardware, you still need to install the software.
- 4:00SPEAKER_01: Precisely.
- 4:01SPEAKER_01: The text emphasizes repeatedly that regenerative medicine is positioned strictly as an adjunct therapy.
- 4:07SPEAKER_00: It's a support system.
- 4:08SPEAKER_01: Right.
- 4:09SPEAKER_01: It is not a replacement for specialist care, for learning support, or for behavioral therapies.
- 4:15SPEAKER_00: The goal is to optimize the biological environment so those traditional therapies can actually take root.
- 4:20SPEAKER_01: Aaron Powell And be more effective over time.
- 4:22SPEAKER_00: Okay.
- 4:22SPEAKER_00: So if the goal is to cool down the hardware and calm the immune system, traditional behavioral therapies can't physically do that.
- 4:28SPEAKER_00: You need a biological tool.
- 4:30SPEAKER_00: Right.
- 4:30SPEAKER_00: And speaking of the tool, I actually loved this little detail from the text.
- 4:34SPEAKER_00: The name Sorona comes from a Celtic goddess of health and protection.
- 4:38SPEAKER_01: Oh yeah.
- 4:39SPEAKER_01: Which really reflects their whole clinical philosophy, actually.
- 4:41SPEAKER_00: Aaron Ross Powell Safe, science-led care over quick fix promises.
- 4:45SPEAKER_01: Exactly.
- 4:46SPEAKER_00: So what exactly is Sarona cell introducing into the body to flip that inflammatory switch?
- 4:52SPEAKER_01: Let's get into the actual science of their approach because the sources are incredibly specific.
- 4:57SPEAKER_00: They are.
- 4:58SPEAKER_01: And honestly, it looks like a bit of an alphabet soup at first glance.
- 5:01SPEAKER_01: They use ethically sourced umbilical cord-derived cells, specifically something called early passage WJMSCs.
- 5:09SPEAKER_00: Aaron Powell Yeah, that is a lot of acronyms.
- 5:11SPEAKER_01: What does that actually mean?
- 5:12SPEAKER_01: Well, it's crucial for understanding the safety profile.
- 5:15SPEAKER_01: MSC stands for mesenchymal stem cells.
- 5:18SPEAKER_00: Okay.
- 5:19SPEAKER_01: And the Dewey J stands for Wharton's Jelly.
- 5:22SPEAKER_00: Wharton's Jelly?
- 5:23SPEAKER_00: That sounds uh interesting.
- 5:25SPEAKER_01: It does.
- 5:26SPEAKER_01: It's the highly active protective connective tissue surrounding the blood vessels inside an umbilical cord.
- 5:31SPEAKER_00: And why the umbilical cord?
- 5:32SPEAKER_00: I mean, why not cells from an adult donor?
- 5:35SPEAKER_01: Because umbilical cord tissue represents day zero biology.
- 5:38SPEAKER_00: Day zero.
- 5:39SPEAKER_01: Yeah.
- 5:40SPEAKER_01: These cells haven't been exposed to decades of environmental toxins, aging, or cellular stress.
- 5:45SPEAKER_00: Aaron Powell That makes sense.
- 5:46SPEAKER_01: They are incredibly robust, highly active, and most importantly, they are immunoprivileged.
- 5:52SPEAKER_00: Meaning what?
- 5:53SPEAKER_00: Exactly.
- 5:53SPEAKER_01: Meaning they have a very low risk of triggering a negative immune response when introduced to a new patient.
- 5:58SPEAKER_00: Wow.
- 5:59SPEAKER_01: And Sorona cell collects these only from healthy full-term deliveries and strictly with donor consent.
- 6:03SPEAKER_00: Okay, so they have these day zero cells, but then the sources go heavy into the lab standards.
- 6:08SPEAKER_01: Oh, extremely heavy.
- 6:09SPEAKER_00: They state these cells are processed under CGMP and ISO 9001 certified quality systems using BSL2 laboratory standards.
- 6:18SPEAKER_00: Right.
- 6:18SPEAKER_00: To a layperson, that just sounds like a bunch of impressive letters.
- 6:21SPEAKER_00: Break that down for us.
- 6:22SPEAKER_01: Aaron Powell It's essentially the difference between a high-end restaurant kitchen and a pharmaceutical clean room.
- 6:29SPEAKER_00: Okay, so way beyond just being clean.
- 6:31SPEAKER_01: Aaron Powell Oh, vastly beyond.
- 6:32SPEAKER_01: BSL2 stands for Biosafety Level 2.
- 6:35SPEAKER_01: Got it.
- 6:36SPEAKER_01: That means they use the exact same rigorous sterility protocols, targeted airflow systems, and protective measures you'd expect in a high-level infectious disease lab.
- 6:47SPEAKER_00: That is intense.
- 6:48SPEAKER_01: Every single batch of cells goes through strict identity, sterility, and viability checks.
- 6:54SPEAKER_00: Viability meaning they ensure the cells are actually alive.
- 6:56SPEAKER_01: Right.
- 6:57SPEAKER_01: Alive and capable of doing their job before they ever reach a patient.
- 7:00SPEAKER_00: And the sources also explicitly state what they do not use, which feels just as important.
- 7:06SPEAKER_00: No embryonic stem cells.
- 7:07SPEAKER_01: None.
- 7:08SPEAKER_00: No experimental pluripotent stem cells.
- 7:10SPEAKER_01: Exactly.
- 7:11SPEAKER_00: And no cells are ever taken from the patient's own brain.
- 7:13SPEAKER_01: Aaron Powell, which is a vital distinction because it dispels a lot of the fear surrounding this field.
- 7:17SPEAKER_00: Aaron Powell Right.
- 7:17SPEAKER_00: But wait, here's where it gets really interesting.
- 7:19SPEAKER_00: And I need to stop you there and push back on this because this is the part that trips people up.
- 7:23SPEAKER_01: Okay, go for it.
- 7:24SPEAKER_00: You're saying they don't take cells from the brain and they don't inject them into the brain.
- 7:29SPEAKER_00: The sources note this is a minimally invasive high V infusion.
- 7:33SPEAKER_00: Correct.
- 7:34SPEAKER_00: They put the stem cells into a vein in the arm via an IV drip.
- 7:40SPEAKER_00: How on earth does an IV drip in the arm help a neurodevelopmental condition like autism?
- 7:46SPEAKER_00: I mean, how does it cross the blood-brain barrier?
- 7:48SPEAKER_00: That sounds biologically impossible.
- 7:50SPEAKER_01: That is the ultimate question.
- 7:52SPEAKER_01: And it is the absolute biggest misconception about stem cell therapy.
- 7:56SPEAKER_00: Right, because people assume the cells are rushing up to the brain.
- 7:59SPEAKER_01: Yes.
- 7:59SPEAKER_01: They assume they cross the barrier and physically build new neurons to replace damaged brain tissue.
- 8:04SPEAKER_00: But that's not it.
- 8:05SPEAKER_01: That is not what is happening at all.
- 8:07SPEAKER_00: So what are they doing when they enter the bloodstream?
- 8:09SPEAKER_01: Remember that immune system overdrive we talked about?
- 8:11SPEAKER_00: The overheating hardware.
- 8:12SPEAKER_01: Exactly.
- 8:13SPEAKER_01: These Wharton's jelly MSCs, they act as a biological support team.
- 8:18SPEAKER_01: When they enter the bloodstream, they interact directly with the body's circulating immune pathways.
- 8:24SPEAKER_00: Like the white blood cells.
- 8:25SPEAKER_01: Right.
- 8:25SPEAKER_01: Your white blood cells, your macrophages, your T cells.
- 8:29SPEAKER_01: Think of these stem cells as tiny biological diplomats.
- 8:33SPEAKER_00: Okay, I'm following.
- 8:34SPEAKER_01: They circulate and release helpful chemical factors that communicate with the patient's overactive immune system.
- 8:40SPEAKER_00: They are talking to the immune system.
- 8:42SPEAKER_01: Yes.
- 8:42SPEAKER_01: They essentially send chemical signals that say, calm down.
- 8:46SPEAKER_01: Halt the severe inflammatory cascade.
- 8:48SPEAKER_00: Wow.
- 8:49SPEAKER_01: By calming that systemic inflammation in the blood and the gut, they lower the overall inflammatory burden on the entire body.
- 8:56SPEAKER_00: And when the systemic inflammation drops, neuroinflammation drops too.
- 9:00SPEAKER_01: Precisely.
- 9:00SPEAKER_01: The inflammation affecting the brain naturally decreases.
- 9:03SPEAKER_01: They don't need to cross the blood-brain barrier to cool down the entire house.
- 9:07SPEAKER_00: Wow.
- 9:08SPEAKER_00: Okay.
- 9:08SPEAKER_00: So they're changing the systemic baseline.
- 9:11SPEAKER_00: And if you're listening to this, think about your own body for a second.
- 9:13SPEAKER_00: Think about when you are highly inflamed.
- 9:15SPEAKER_01: Yeah, like a terrible flu.
- 9:16SPEAKER_00: Or a severe allergic reaction or a massive gut infection.
- 9:20SPEAKER_00: Your focus is entirely shot.
- 9:22SPEAKER_01: Your sleep suffers immensely.
- 9:24SPEAKER_00: You might be irritable, cranky, or have terrible brain fog.
- 9:28SPEAKER_00: You cannot learn or engage socially when your body is sounding a systemic alarm.
- 9:32SPEAKER_01: Aaron Powell You just can't.
- 9:34SPEAKER_01: Now imagine feeling a version of that systemic biological alarm every single day of your life.
- 9:41SPEAKER_00: Aaron Powell Which is the reality for many individuals on the autism spectrum.
- 9:45SPEAKER_01: Trevor Burrus Exactly.
- 9:46SPEAKER_01: By using these cells to lower that baseline inflammation, the goal is to create a more regulated internal environment.
- 9:53SPEAKER_00: And when the physical environment is calmer, the individual suddenly has a better baseline for learning.
- 9:58SPEAKER_01: Aaron Powell For getting restorative sleep.
- 10:00SPEAKER_00: And for self-regulating their behavior.
- 10:01SPEAKER_01: Trevor Burrus, it's a huge shift.
- 10:03SPEAKER_00: So understanding that biological mechanism makes total sense.
- 10:06SPEAKER_00: But practically speaking, what does this actually look like for a family?
- 10:10SPEAKER_00: Aaron Powell It's a big question.
- 10:11SPEAKER_00: Aaron Powell Right.
- 10:11SPEAKER_00: Because if you're listening to this and you spent years shuttling between local speech and occupational therapists, the idea of traveling for a cellular 5e drip is a massive undertaking.
- 10:20SPEAKER_01: Oh, absolutely.
- 10:21SPEAKER_00: The sources note that Cyron cell is based in Cyberjaya, Malaysia, and they attract a huge number of international patients.
- 10:28SPEAKER_01: Aaron Powell Yeah, they specifically mention families flying in from places like Australia and the Middle East.
- 10:33SPEAKER_00: That is a massive logistical and emotional hurdle.
- 10:36SPEAKER_01: It absolutely is.
- 10:37SPEAKER_01: And that's exactly why their patient journey is structured the way it is.
- 10:41SPEAKER_01: It's not a walk-in clinic where you just show up and get an IV.
- 10:44SPEAKER_01: No.
- 10:44SPEAKER_01: They operate with a multidisciplinary medical team.
- 10:48SPEAKER_01: We are talking about physicians from internal medicine, neurology, rehabilitation, and sports medicine.
- 10:54SPEAKER_00: All consulting on these cases.
- 10:56SPEAKER_01: Right.
- 10:56SPEAKER_01: But perhaps just as importantly for families traveling overseas, they have a dedicated patient liaison and nursing team.
- 11:04SPEAKER_00: Meaning you aren't just left to figure out medical tourism aspect on your own.
- 11:08SPEAKER_01: Exactly.
- 11:09SPEAKER_01: They actively coordinate the travel advice, the appointment schedules, and the day-to-day details.
- 11:14SPEAKER_00: So the family isn't entirely overwhelmed by the logistics of being in a foreign country for medical care?
- 11:19SPEAKER_01: Right.
- 11:20SPEAKER_01: And the procedure itself, as we touched on, is minimally invasive.
- 11:24SPEAKER_00: There is no open surgery.
- 11:25SPEAKER_01: No, most patients literally just sit and relax in a treatment chair.
- 11:29SPEAKER_00: Maybe watch an iPad or read a book.
- 11:31SPEAKER_01: Yeah.
- 11:31SPEAKER_01: Well the cells are administered slowly through a vein using a standard IV drip.
- 11:35SPEAKER_00: But before a patient even gets into that chair, there is a practice detailed in these sources that I found radically transparent.
- 11:42SPEAKER_01: Oh, the screening process.
- 11:43SPEAKER_00: Yes.
- 11:44SPEAKER_00: Especially for a private medical center.
- 11:46SPEAKER_00: They explicitly state that they will tell patients if they are not a good fit for the program.
- 11:51SPEAKER_00: They actively turn paying patients away.
- 11:54SPEAKER_01: Yes.
- 11:55SPEAKER_01: And this is a hallmark of transparent, evidence-based regenerative medicine.
- 12:00SPEAKER_00: Turning away paying patients is not exactly a common business model in the broader wellness industry.
- 12:04SPEAKER_01: Definitely not.
- 12:06SPEAKER_01: But Sarona cell requires a deep, intensive medical evaluation before anyone is approved for travel.
- 12:14SPEAKER_00: What are they looking for in that evaluation?
- 12:16SPEAKER_01: They review the specific diagnosis, the child or adult's entire medical history, their allergies, their current meditations, and their daily functional baseline at home and school.
- 12:26SPEAKER_01: Suitability depends heavily on assessing safety risks and ensuring there are clear, achievable goals.
- 12:31SPEAKER_00: And if they don't see that.
- 12:32SPEAKER_01: If the medical team believes the patient's specific biological profile won't benefit from the therapy, they say no.
- 12:39SPEAKER_00: Their stated priority is building long-term clinical trust, not just booking one-time procedures.
- 12:45SPEAKER_01: Which is incredibly refreshing.
- 12:46SPEAKER_00: It sets a hard boundary against the miracle cure hype.
- 12:50SPEAKER_00: And speaking of realistic goals, they are very careful about how they define success.
- 12:55SPEAKER_00: They state point blank that autism is not a disease with a single cure.
- 13:01SPEAKER_01: Right.
- 13:01SPEAKER_01: They do not claim to cure autism.
- 13:03SPEAKER_00: Because autism is a lifelong neurodevelopmental condition.
- 13:06SPEAKER_00: Trevor Burrus, Jr.
- 13:06SPEAKER_01: Exactly.
- 13:07SPEAKER_01: So instead of looking for a cure, they are tracking very specific, realistic quality of life metrics post-treatment.
- 13:15SPEAKER_00: Like what?
- 13:16SPEAKER_01: They are looking for improvements in sleep quality and duration.
- 13:19SPEAKER_01: They are looking for improvements in digestion and gut comfort.
- 13:22SPEAKER_00: Increased calmness.
- 13:23SPEAKER_01: Better attention spans and more active social engagement.
- 13:26SPEAKER_00: They are tracking whether the patient's day-to-day life has functionally improved because the biological hardware is no longer overheating.
- 13:32SPEAKER_01: Precisely.
- 13:33SPEAKER_00: But relying on that kind of strict patient screening and tracking those very specific quality of life metrics requires an evidence-based foundation.
- 13:42SPEAKER_01: You can't just guess that this works and hope for the best.
- 13:45SPEAKER_00: Exactly.
- 13:46SPEAKER_00: So what does the broader clinical research actually say about all this?
- 13:51SPEAKER_00: The sources point out something really crucial here.
- 13:54SPEAKER_00: Families want to see human data.
- 13:56SPEAKER_01: Oh, for sure.
- 13:57SPEAKER_01: Animal trials are a vital part of early medical research.
- 14:01SPEAKER_01: But when you are talking about complex human behaviors, right, social communication and neurodevelopment, a mouse model can only tell you so much.
- 14:09SPEAKER_00: Families want to know what happens when these specific protocols are applied to human beings.
- 14:14SPEAKER_01: And the sources highlight two major clinical studies that help form the foundation of this entire therapeutic approach.
- 14:20SPEAKER_00: Right, let's look at the first one.
- 14:21SPEAKER_00: It's a landmark study from Duke University in the United States.
- 14:25SPEAKER_00: They explored something slightly different from Cyrona's exact method, but highly relevant.
- 14:30SPEAKER_01: Autologous umbilical cord blood infusions.
- 14:32SPEAKER_00: Yes.
- 14:33SPEAKER_00: For autism spectrum disorder.
- 14:35SPEAKER_00: Now, autologous means using the child's own cord blood.
- 14:38SPEAKER_01: Assuming the parents had the foresight and resources to bank it at birth.
- 14:42SPEAKER_00: Right.
- 14:42SPEAKER_00: And the Duke researchers were specifically looking at two things.
- 14:46SPEAKER_00: First, is this infusion safe?
- 14:49SPEAKER_01: And second, does it support measurable improvements in behavior and social communication in children on the spectrum?
- 14:56SPEAKER_00: And the results were incredibly promising on both fronts.
- 14:59SPEAKER_01: They showed that cellular infusions could safely yield observable behavioral improvements.
- 15:04SPEAKER_00: But the limitation there is the word autologous.
- 15:07SPEAKER_00: Not everyone banks their child's cord blood at birth.
- 15:10SPEAKER_01: In fact, the vast majority of people don't.
- 15:13SPEAKER_00: Which brings us to the second major study reference, which comes from Metastem in Panama.
- 15:18SPEAKER_01: Yes.
- 15:18SPEAKER_01: And this study is much closer to the MSc approach that Cerroni uses.
- 15:22SPEAKER_00: Right.
- 15:22SPEAKER_00: They evaluated the safety and feasibility of using derived umbilical cord mesenchymal stromal cells.
- 15:29SPEAKER_01: Meaning cells from a healthy donor cord, not the child's own banked blood.
- 15:32SPEAKER_00: Aaron Powell They evaluated this specifically in children with autism.
- 15:36SPEAKER_00: So what did these studies actually prove?
- 15:38SPEAKER_00: Are they the definitive final answer on stem cells and autism?
- 15:42SPEAKER_01: Aaron Ross Powell Well, what's fascinating here is that the sources are, again, very restrained and medically appropriate.
- 15:48SPEAKER_00: They don't claim these studies are the final word.
- 15:50SPEAKER_01: No, they acknowledge that larger multiphase clinical trials are still developing globally.
- 15:55SPEAKER_00: And are absolutely needed.
- 15:57SPEAKER_01: Right.
- 15:57SPEAKER_01: But these early human studies are critical.
- 16:00SPEAKER_01: They establish feasibility and they prove safety.
- 16:03SPEAKER_00: They prove that this isn't just theoretical biology.
- 16:06SPEAKER_01: Exactly.
- 16:07SPEAKER_01: There is a human evidence base that is actively guiding how modern treatments are structured and how safety standards are designed today.
- 16:15SPEAKER_00: It's building the foundation of proof, step by step, human by human.
- 16:20SPEAKER_00: Now, before we wrap up, there is one last surprising detail in the sources that I want to bring up.
- 16:24SPEAKER_00: Okay.
- 16:25SPEAKER_00: And it's something Serona Cell offers as an added value service alongside the main stem cell therapy.
- 16:31SPEAKER_01: Uh, the exosome therapy.
- 16:32SPEAKER_00: Yes.
- 16:33SPEAKER_00: I see this word popping up everywhere in regenerative medicine lately.
- 16:36SPEAKER_00: So what does this all mean?
- 16:37SPEAKER_00: What on earth are exosomes?
- 16:39SPEAKER_01: Exosomes are arguably one of the most fascinating advancements in cellular biology right now.
- 16:45SPEAKER_01: Oh, absolutely.
- 16:46SPEAKER_01: Remember our analogy of the stem cells being biological diplomats that release chemical signals?
- 16:52SPEAKER_00: Right.
- 16:52SPEAKER_00: To calm the immune system, they float around and tell the white blood cells to start panicking.
- 16:56SPEAKER_01: Aaron Ross Powell Well, exosomes are the actual signals.
- 16:59SPEAKER_00: Wait, really?
- 17:00SPEAKER_01: Yes.
- 17:00SPEAKER_01: They are these tiny microscopic vesicles, essentially little messenger packets, that are released by the stem cells.
- 17:07SPEAKER_00: Oh, wow.
- 17:08SPEAKER_01: They are packed with helpful cellular information, lipids, and growth factors.
- 17:13SPEAKER_00: So they carry the message.
- 17:14SPEAKER_01: Exactly.
- 17:15SPEAKER_01: But here is the real aha moment with exosomes.
- 17:18SPEAKER_01: They are a cellular.
- 17:19SPEAKER_00: A cellular, meaning they aren't actual cells.
- 17:23SPEAKER_01: Right.
- 17:23SPEAKER_01: They are messages without the messenger.
- 17:25SPEAKER_00: That's wild.
- 17:26SPEAKER_01: Because they don't contain a nucleus or live DNA, the risk of the body rejecting them is virtually zero.
- 17:32SPEAKER_00: Okay, that makes sense.
- 17:33SPEAKER_01: By utilizing exosome therapy alongside the live MSCs, you are essentially flooding the biological environment with these concentrated, highly targeted calming and repairing messages.
- 17:44SPEAKER_00: Further supporting the goal of regulating that severe inflammation.
- 17:47SPEAKER_00: That is incredible.
- 17:48SPEAKER_00: So to stick with our analogy, it's like sending the biological diplomats, but also flooding the zone with a massive stack of highly detailed policy briefs to make absolutely sure the anti-inflammatory message gets through.
- 18:02SPEAKER_01: Loud and clear.
- 18:03SPEAKER_01: That's exactly it.
- 18:04SPEAKER_00: It's a strategic additive approach designed to maximize the biological support without increasing the risk profile.
- 18:11SPEAKER_01: Precisely.
- 18:12SPEAKER_00: Okay.
- 18:12SPEAKER_00: We have covered a massive amount of ground today.
- 18:15SPEAKER_00: Let's pull this all together.
- 18:16SPEAKER_00: We've explored how CironaCell, a doctor-led center in Malaysia, is navigating that incredibly complex and often murky world of regenerative medicine.
- 18:25SPEAKER_00: Right.
- 18:26SPEAKER_00: They are using highly screened, ethically sourced Wharton's jelly umbilical cord cells and cellular exosomes, not as some mythical magic cure for autism, but as a biological support system.
- 18:42SPEAKER_00: They are aiming to cool down the hardware.
- 18:43SPEAKER_00: They want to improve the baseline quality of life, better sleep, calmer digestion, improved focus.
- 18:48SPEAKER_01: And they're doing it within a framework of rigorous transparency.
- 18:52SPEAKER_01: They are relying on human clinical data, enforcing strict BSL2 lab standards, and showing a willingness to actually tell patients when a treatment isn't a good fit.
- 19:01SPEAKER_01: Which is so rare.
- 19:02SPEAKER_01: It is.
- 19:03SPEAKER_01: So when you hear about regenerative medicine in the future, what stands out to you?
- 19:07SPEAKER_01: Will you fall for the loud, internet hype promises of an overnight miracle, or will you look for the structured, transparent, and frankly much more cautious medical screening process we discussed today?
- 19:19SPEAKER_00: It really changes how you evaluate medical claims online.
- 19:22SPEAKER_00: And it leaves me with one final thought to Mullover.
- 19:24SPEAKER_01: Oh, up to that.
- 19:25SPEAKER_00: We started by talking about how traditional medicine loves clean lines and easy diagnoses.
- 19:30SPEAKER_01: Right.
- 19:31SPEAKER_00: But autism requires us to look at the incredibly complex environment of the whole body.
- 19:36SPEAKER_00: If introducing cellular messengers can alter the body's inflammatory hardware enough to potentially improve things like sleep, attention, and social engagement in autism, well, it raises an incredible question.
- 19:48SPEAKER_00: How many other neurodevelopmental or behavioral conditions are we currently treating purely as isolated brain issues when we should really be looking at the health of the entire biological system?
- 19:59SPEAKER_01: Wow.
- 20:00SPEAKER_01: It's a vital question.
- 20:01SPEAKER_01: And one we need to keep asking as this science continues to evolve.
- 20:04SPEAKER_00: Thanks for joining us on this deep dive.
- 20:06SPEAKER_00: We'll catch you next time.